Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NOR-SWITCH Results ‘Concerning’ In Crohn’s Disease, Says Janssen

Nov 11 2016

• By Ian Schofield

Paths — How far should biosimilars be interchangeable?

Related Content

Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA

Nov 01 2016

Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Oct 20 2016

Related Companies

Johnson & Johnson

Additional Topics

United States Biosimilars Safety Clinical Trials Regulation Inflammation

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window